small molecule

VANFLYTA

QUIZARTINIB DIHYDROCHLORIDE

Loss of exclusivitySeptember 2033latest FDA-listed patent expiry

CompanyDaiichi Sankyo →See this company's full patent-cliff portfolio

Drug detail

Brand name	VANFLYTA
Active ingredient	QUIZARTINIB DIHYDROCHLORIDE
Strength	EQ 17.7MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
9675549	September 2033	product
8357690	February 2031	use U-3661
9555040	May 2030	use U-3661
8836218	March 2030	use U-3661
7968543	August 2029	product
8865710	August 2029	product
7820657	September 2028	substance
8129374	March 2027	use U-3661
8883783	March 2027	substance
8557810	March 2027	product
9585892	March 2027	use U-3661

Regulatory exclusivity

Code	Expires
ODE-437	July 2030
NCE	July 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Daiichi Sankyo